NASDAQ:SLXN

Silexion Therapeutics (SLXN) Stock Price, News & Analysis

Silexion Therapeutics logo
$1.44 -0.21 (-12.73%)
Closing price 04:00 PM Eastern
Extended Trading
$1.56 +0.12 (+8.33%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Silexion Therapeutics Stock (NASDAQ:SLXN)

Advanced

Key Stats

Today's Range
$1.44
▼
$1.65
50-Day Range
$1.65
▼
$13.06
52-Week Range
$1.44
▼
$777.12
Volume
23,739 shs
Average Volume
133,896 shs
Market Capitalization
$331.20 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Silexion Therapeutics is an Israel-based clinical-stage biotechnology company developing RNA interference (RNAi) treatments for cancers associated with mutations in the KRAS gene. Its approach is designed to reduce the activity of cancer-related genes rather than target tumors with conventional drug therapies.

The company’s lead candidate, SIL-204, is being developed for pancreatic cancer. It is an investigational treatment, and Silexion has not established a commercial product portfolio.

Silexion’s work is focused on research and clinical development; its treatments are not approved for routine commercial use. The company’s shares trade on the Nasdaq under the symbol SLXN.

AI Generated. May Contain Errors.

Silexion Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

SLXN MarketRank™: 
1.44189765458 of 5 stars

Silexion Therapeutics scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Silexion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Silexion Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Silexion Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Silexion Therapeutics are expected to grow in the coming year, from ($112.71) to ($44.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Silexion Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Silexion Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Silexion Therapeutics has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.48% of the float of Silexion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Silexion Therapeutics has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Silexion Therapeutics has recently decreased by 49.52%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Silexion Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Silexion Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Silexion Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Silexion Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Silexion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Silexion Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.30% of the stock of Silexion Therapeutics is held by insiders.

  • Percentage Held by Institutions

    10.95% of the stock of Silexion Therapeutics is held by institutions.

  • Read more about Silexion Therapeutics' insider trading history.
Receive SLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SLXN Stock News Headlines

Wall Street Zen Upgrades Silexion Therapeutics (NASDAQ:SLXN) to "Hold"
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Silexion Therapeutics (SLXN) Projected to Post Earnings on Wednesday
Silexion Therapeutics Announces 1-for-24 Reverse Share Split
See More Headlines

SLXN Stock Analysis - Frequently Asked Questions

Silexion Therapeutics' stock was trading at $460.80 on January 1st, 2026. Since then, SLXN shares have decreased by 99.7% and is now trading at $1.4470.

Silexion Therapeutics Corp (NASDAQ:SLXN) issued its earnings results on Thursday, November, 12th. The company reported ($13.70) earnings per share for the quarter, topping analysts' consensus estimates of ($218.40) by $204.70.

Silexion Therapeutics's stock reverse split before market open on Sunday, July 27th 2025.The 1-15 reverse split was announced on Sunday, July 27th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SLXN
Previous Symbol
NASDAQ:SLXN
CIK
2022416
Employees
14
Year Founded
2024

Profitability

EPS (Trailing Twelve Months)
($42.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.91 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-895.97%
Return on Assets
-231.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.66
Quick Ratio
1.66

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.80 per share
Price / Book
0.11

Miscellaneous

Outstanding Shares
230,000
Free Float
231,000
Market Cap
$331.20 thousand
Optionable
N/A
Beta
-0.30

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:SLXN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners